Over 300 experiments and 5 years in the making. That's what it took to bring XLEAP-SBS chemistry to life. Adam Culley, Senior Scientist at Illumina, reflects on how it all came together.
Illumina
Biotechnology Research
San Diego, CA 482,908 followers
Unlocking the Power of the Genome
About us
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
- Website
-
http://www.illumina.com
External link for Illumina
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- San Diego, CA
- Type
- Public Company
- Founded
- 1998
Products
BaseSpace Clarity LIMS
Laboratory Information Management Systems (LIMS)
BaseSpace Clarity LIMS is a laboratory information management system that helps genomics labs track samples and manage workflows for an optimized and efficient lab.
Locations
Employees at Illumina
Updates
-
Q² Solutions, a global leader in clinical trials and research, has validated the Illumina TruSight™ Oncology Comprehensive (EU) test, or TSO Comp, at their Edinburgh site. This CE-marked IVD solution offers comprehensive genomic profiling of DNA, RNA variants, microsatellite instability, and tumor mutational burden across various solid tumors. With this validation, Q² Solutions is taking tumor profiling to the next level, empowering clinical trials to select European patients based on specific biomarkers, bringing treatments to patients faster and more effectively. Learn more: https://bit.ly/4eh8hZY
-
With nearly 96 million people in India affected by rare diseases and 1 in 9 facing cancer in their lifetime, the need for innovative health solutions is critical. That’s why over 200 of India’s brightest scientific minds gathered at the Illumina Genomics Summit to share groundbreaking advancements in genomics and multiomics. Find out how we’re expanding access to genomics and hiring opportunities in India: https://bit.ly/4gkV1oU
-
What happens when you combine the power of genomics with the dedication of citizen scientists at scale? You create powerful datasets to understand and improve the health of our world’s oceans. That’s exactly what Xavier Pochon from the Cawthron Institute and the Citizens of The Sea project aims to do – outfitting seafaring vessels across the South-West Pacific region with environmental DNA (eDNA) sample collection kits and pairing it with the sequencing expertise of Sequench laboratory in New Zealand. See more of their work: https://bit.ly/4e7d7sE
-
Why are researchers making the switch to next-generation sequencing from traditional molecular biology methods? We're glad you asked: https://bit.ly/3WUKWq6
-
What do our employees’ kids think their parents do all day at work? Hear their creative guesses and surprising reactions to what they learned after #BringYourKidToWorkDay. Shout out to all the parents at Illumina who do stuff with DNA – we know it is more complicated than that, but you clearly make it sound easy. #IlluminaProud #Genomics4All
-
We are proud to support Professor Niall Corcoran and his team in this critical project. #Genomics4All
Prof Niall Corcoran's TAGC Innovation Project gets to the minutiae of cancer research. His research team use cutting-edge #genomic technologies to analyse the DNA of early stage #ProstateCancer tumours, part of a new University of Melbourne & Illumina partnership.
-
There’s much more to come for Illumina and next-generation sequencing. Jacob Thaysen shares his strategic vision to lead us into the next era.
Affiliated pages
Similar pages
Browse jobs
Stock
ILMN
NASDAQ
20 minutes delay
$129.18
2.93 (2.321%)
- Open
- 126.31
- Low
- 126.31
- High
- 129.71
Data from Refinitiv
See more info on